Pyxis Oncology

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Simcere Pharmaceutical Group 's novel recombinant anti-VEGF antibody suvemcitug has shown a promising overall survival trend in still immature data in platinum-resistant ovarian cancer presented at th

It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l

Tagworks Pharmaceuticals , a pioneer of click-to-release chemistry, has raised $65m in a series A round to finance a pipeline targeted at unlocking the therapeutic potential of antibody-drug conjugate